Head to Head Comparison: Alphatec (NASDAQ:ATEC) versus IceCure Medical (NASDAQ:ICCM)

IceCure Medical (NASDAQ:ICCM) and Alphatec (NASDAQ:ATEC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Earnings & Valuation

This table compares IceCure Medical and Alphatec”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38 million	1.76	-$15.06 million	($8.52)	-0.20
Alphatec	$764.16 million	2.05	-$143.36 million	($0.71)	-14.25

IceCure Medical has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IceCure Medical and Alphatec’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
Alphatec	-13.49%	-6,752.24%	-13.88%

Analyst Ratings

This is a breakdown of current recommendations and price targets for IceCure Medical and Alphatec, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	2	0	3	0	2.20
Alphatec	1	1	13	0	2.80

IceCure Medical presently has a consensus target price of $52.50, indicating a potential upside of 2,934.68%. Alphatec has a consensus target price of $17.40, indicating a potential upside of 71.94%. Given IceCure Medical’s higher possible upside, research analysts plainly believe IceCure Medical is more favorable than Alphatec.

Insider & Institutional Ownership

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 66.3% of Alphatec shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 13.5% of Alphatec shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

IceCure Medical has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Summary

Alphatec beats IceCure Medical on 10 of the 14 factors compared between the two stocks.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About Alphatec

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.